The Medicines Company is conducting several development programs with planned and executed clinical trials. We believe our pipeline of products in development can satisfy unmet medical needs in the acute and intensive care hospital market.
Cangrelor — an intravenous small molecule antiplatelet agent. Submitted in the US and EU for approval.
IONSYS (fentanyl iontophoretic transdermal system) — a compact, disposable, needleless patient-controlled system. Submitted in the US for approval. EU submission expected Q3 2014.
Raplixa — a dry powder topical formulation of fibrinogen and thrombin. Submitted in the US and EU for approval.
RPX-602 — a proprietary reformulation of Minocin IV, a tetracycline-class antibiotic, utilizing magnesium sulfate that enables administration of minocycline in smaller volumes of fluids, and may improve the local tolerability of intravenous infusions.
MDCO-216 or ApoA-1 Milano — a novel biologic that is a naturally occurring variant of a protein found in human high-density lipoprotein.
Carbavance — an antibiotic agent.
ALN-PCSsc — a subcutaneously administered RNA interference therapeutic.